Patients receiving low-potential emetogenic chemotherapy develop CINV ___% to ___% of the time.

Patients receiving low-potential emetogenic chemotherapy are estimated to develop chemotherapy-induced nausea and vomiting (CINV) in a range of 10% to 30% of the time. This percentage is based on clinical studies that classify emetogenic potential into different categories, with low-potential emetogenic regimens being one of them.

In understanding the specific range of 10% to 30%, it's important to recognize that while low emetogenicity implies a lower risk compared to moderate or highly emetogenic chemotherapy agents, patients can still experience CINV. This phenomenon is influenced by factors including the specific drug used, the patient's individual characteristics, and their previous experiences with CINV. It is significant for healthcare providers to be aware of this range to effectively counsel and manage patients undergoing treatment.

Other options either overestimate or underestimate the occurrence of CINV associated with low-potential emetogenic chemotherapy. Thus, understanding the correct incidence range helps in providing the right anticipatory guidance and interventions to minimize discomfort for the patient during treatment.